Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.
Low molecular weight heparin for the prevention of severe preeclampsia : where next? / K. Mclaughlin, R.R. Scholten, J.D. Parker, E. Ferrazzi, J.C.P. Kingdom. - In: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0306-5251. - 84:4(2018), pp. 673-678. [10.1111/bcp.13483]
Low molecular weight heparin for the prevention of severe preeclampsia : where next?
E. Ferrazzi;
2018
Abstract
Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.
| File | Dimensione | Formato | |
|---|---|---|---|
|
McLaughlin_et_al-2018-British_Journal_of_Clinical_Pharmacology.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
361.85 kB
Formato
Adobe PDF
|
361.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
